{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:04:26Z","timestamp":1779905066453,"version":"3.53.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03909-x","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:35:12Z","timestamp":1744612512000},"page":"3625-3635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The therapeutic efficacy and application prospects of tumor-treating fields (TTFields) in resolving malignant tumors of central nervous system"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-1486","authenticated-orcid":false,"given":"Wei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"3909_CR1","doi-asserted-by":"publisher","unstructured":"Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen P. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest 2023;133:e163446. https:\/\/doi.org\/10.1172\/JCI163446","DOI":"10.1172\/JCI163446"},{"key":"3909_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9:29. https:\/\/doi.org\/10.1038\/s41572-023-00439-0.","journal-title":"Nat Rev Dis Primers"},{"key":"3909_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/neuonc\/noad205","volume":"26","author":"S Coy","year":"2024","unstructured":"Coy S, Lee JS, Chan SJ, Woo T, Jones J, Alexandrescu S, Wen PY, Sorger PK, Ligon KL, Santagata S. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors. Neuro Oncol. 2024;26:458\u201372. https:\/\/doi.org\/10.1093\/neuonc\/noad205.","journal-title":"Neuro Oncol"},{"key":"3909_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11060-021-03749-z","volume":"153","author":"K Bender","year":"2021","unstructured":"Bender K, Perez E, Chirica M, Onken J, Kahn J, Brenner W, Ehret F, Euskirchen P, Koch A, Capper D, Kaul D. High-grade astrocytoma with piloid features (HGAP): the Charite experience with a new central nervous system tumor entity. J Neurooncol. 2021;153:109\u201320. https:\/\/doi.org\/10.1007\/s11060-021-03749-z.","journal-title":"J Neurooncol"},{"key":"3909_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3322\/caac.21693","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381\u2013406. https:\/\/doi.org\/10.3322\/caac.21693.","journal-title":"CA Cancer J Clin"},{"key":"3909_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/cco-23-82","volume":"12","author":"T Kutuk","year":"2023","unstructured":"Kutuk T, Atak E, La Rosa A, Kotecha R, Mehta MP, Chuong MD. Tumor treating fields: narrative review of a promising treatment modality for cancer. Chin Clin Oncol. 2023;12:64. https:\/\/doi.org\/10.21037\/cco-23-82.","journal-title":"Chin Clin Oncol"},{"key":"3909_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13046-023-02642-z","volume":"42","author":"S Xu","year":"2023","unstructured":"Xu S, Luo C, Chen D, Tang L, Cheng Q, Chen L, Liu Z. circMMD reduction following tumor treating fields inhibits glioblastoma progression through FUBP1\/FIR\/DVL1 and miR-15b-5p\/FZD6 signaling. J Exp Clin Cancer Res. 2023;42:64. https:\/\/doi.org\/10.1186\/s13046-023-02642-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"3909_CR8","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","volume":"12","author":"M Giladi","year":"2017","unstructured":"Giladi M, Munster M, Schneiderman RS, Voloshin T, Porat Y, Blat R, Zielinska-Chomej K, Haag P, Bomzon Z, Kirson ED, Weinberg U, Viktorsson K, Lewensohn R, Palti Y. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017;12:206. https:\/\/doi.org\/10.1186\/s13014-017-0941-6.","journal-title":"Radiat Oncol"},{"key":"3909_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4049\/jimmunol.2100100","volume":"207","author":"G Diamant","year":"2021","unstructured":"Diamant G, Simchony Goldman H, Gasri Plotnitsky L, Roitman M, Shiloach T, Globerson-Levin A, Eshhar Z, Haim O, Pencovich N, Grossman R, Ram Z, Volovitz I. T cells retain pivotal antitumoral functions under tumor-treating electric fields. J Immunol. 2021;207:709\u201319. https:\/\/doi.org\/10.4049\/jimmunol.2100100.","journal-title":"J Immunol"},{"key":"3909_CR10","doi-asserted-by":"publisher","unstructured":"Barsheshet Y, Voloshin T, Brant B, Cohen G, Koren L, Blatt R, Cahal S, Haj Khalil T, Zemer Tov E, Paz R, Klein-Goldberg A, Tempel-Brami C, Jacobovitch S, Volodin A, Kan T, Koltun B, David C, Haber A, Giladi M, Weinberg U, Palti Y. Tumor Treating Fields (TTFields) concomitant with immune checkpoint inhibitors are therapeutically effective in non-small cell lung cancer (NSCLC) in vivo model. Int J Mol Sci 2022;23:14073. https:\/\/doi.org\/10.3390\/ijms232214073","DOI":"10.3390\/ijms232214073"},{"key":"3909_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41420-018-0130-x","volume":"4","author":"E Chang","year":"2018","unstructured":"Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, Zeng Y, Joubert LM, Arami H, Natarajan A, Sinclair R, Gambhir SS. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov. 2018;4:113. https:\/\/doi.org\/10.1038\/s41420-018-0130-x.","journal-title":"Cell Death Discov"},{"key":"3909_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/19714009231207083","volume":"37","author":"M Iv","year":"2024","unstructured":"Iv M, Naya L, Sanan S, Van Buskirk SL, Nagpal S, Thomas RP, Recht LD, Patel CB. Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma. Neuroradiol J. 2024;37:107\u201318. https:\/\/doi.org\/10.1177\/19714009231207083.","journal-title":"Neuroradiol J"},{"key":"3909_CR13","doi-asserted-by":"publisher","unstructured":"Salvador E, Koppl T, Hormann J, Schonharl S, Bugaeva P, Kessler AF, Burek M, Ernestus RI, Lohr M, Hagemann C. Tumor treating fields (TTFields) induce cell junction alterations in a human 3D in vitro model of the blood-brain barrier. Pharmaceutics 2023;15:185 https:\/\/doi.org\/10.3390\/pharmaceutics15010185","DOI":"10.3390\/pharmaceutics15010185"},{"key":"3909_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-020-03540-6","volume":"148","author":"W Shi","year":"2020","unstructured":"Shi W, Blumenthal DT, Oberheim Bush NA, Kebir S, Lukas RV, Muragaki Y, Zhu JJ, Glas M. Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. J Neurooncol. 2020;148:489\u2013500. https:\/\/doi.org\/10.1007\/s11060-020-03540-6.","journal-title":"J Neurooncol"},{"key":"3909_CR15","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","volume":"20","author":"GL Ceresoli","year":"2019","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crino L, Krzakowski M, Russel J, Maconi A, Gianoncelli L, Grosso F. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20:1702\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30532-7.","journal-title":"Lancet Oncol"},{"key":"3909_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00584-3","volume":"24","author":"T Leal","year":"2023","unstructured":"Leal T, Langer C. Tumor treating fields therapy in metastatic non-small-cell lung cancer - Authors\u2019 reply. Lancet Oncol. 2023;24: e454. https:\/\/doi.org\/10.1016\/S1470-2045(23)00584-3.","journal-title":"Lancet Oncol"},{"key":"3909_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12935-023-02959-x","volume":"23","author":"AR Smothers","year":"2023","unstructured":"Smothers AR, Henderson JR, O\u2019Connell JJ, Stenbeck JM, Dean D, Booth BW. Optimization of tumor-treating field therapy for triple-negative breast cancer cells in vitro via frequency modulation. Cancer Cell Int. 2023;23:110. https:\/\/doi.org\/10.1186\/s12935-023-02959-x.","journal-title":"Cancer Cell Int"},{"key":"3909_CR18","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104:10152\u20137. https:\/\/doi.org\/10.1073\/pnas.0702916104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3909_CR19","doi-asserted-by":"publisher","unstructured":"Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, Zeevi E, Frechtel-Gerzi R, Ene H, Dor-On E, Voloshin T, Tzchori I, Haber A, Giladi M, Kinzel A, Weinberg U, Palti Y. Tumor treating fields (TTFields) concomitant with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo. Cancers 2022;14:2959 https:\/\/doi.org\/10.3390\/cancers14122959","DOI":"10.3390\/cancers14122959"},{"key":"3909_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.738801","volume":"11","author":"L Bai","year":"2021","unstructured":"Bai L, Pfeifer T, Gross W, De La Torre C, Zhao S, Liu L, Schaefer M, Herr I. Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer. Front Oncol. 2021;11: 738801. https:\/\/doi.org\/10.3389\/fonc.2021.738801.","journal-title":"Front Oncol"},{"key":"3909_CR21","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.21037\/tcr-21-1853","volume":"11","author":"EH Kim","year":"2022","unstructured":"Kim EH, Lee WS, Oh HK. Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT\/STAT3 signaling. Transl Cancer Res. 2022;11:2553\u201361. https:\/\/doi.org\/10.21037\/tcr-21-1853.","journal-title":"Transl Cancer Res"},{"key":"3909_CR22","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1002\/ijc.30406","volume":"139","author":"T Voloshin","year":"2016","unstructured":"Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, Giladi M, Schneiderman RS, Zeevi E, Porat Y, Bomzon Z, Urman N, Itzhaki A, Cahal S, Kirson ED, Weinberg U, Palti Y. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer. 2016;139:2850\u20138. https:\/\/doi.org\/10.1002\/ijc.30406.","journal-title":"Int J Cancer"},{"key":"3909_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3892\/etm.2023.12062","volume":"26","author":"WS Lee","year":"2023","unstructured":"Lee WS, Jang Y, Cho A, Kim YB, Bu YH, Yang S, Kim EH. Effectiveness of tumor-treating fields to reduce the proliferation and migration of liposarcoma cell lines. Exp Ther Med. 2023;26:363. https:\/\/doi.org\/10.3892\/etm.2023.12062.","journal-title":"Exp Ther Med"},{"key":"3909_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ijc.32483","volume":"146","author":"J Ye","year":"2020","unstructured":"Ye J, Zhu J, Chen H, Qian J, Zhang L, Wan Z, Chen F, Sun S, Li W, Luo C. A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. Int J Cancer. 2020;146:248\u201361. https:\/\/doi.org\/10.1002\/ijc.32483.","journal-title":"Int J Cancer"},{"key":"3909_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/iub.2212","volume":"72","author":"C Qu","year":"2020","unstructured":"Qu C, Yan C, Cao W, Li F, Qu Y, Guan K, Si C, Yu Z, Qu Z. miR-128-3p contributes to mitochondrial dysfunction and induces apoptosis in glioma cells via targeting pyruvate dehydrogenase kinase 1. IUBMB Life. 2020;72:465\u201375. https:\/\/doi.org\/10.1002\/iub.2212.","journal-title":"IUBMB Life"},{"key":"3909_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ymthe.2019.11.015","volume":"28","author":"F Zhang","year":"2020","unstructured":"Zhang F, Ruan X, Ma J, Liu X, Zheng J, Liu Y, Liu L, Shen S, Shao L, Wang D, Yang C, Cai H, Li Z, Feng Z, Xue Y. DGCR8\/ZFAT-AS1 promotes CDX2 transcription in a PRC2 complex-dependent manner to facilitate the malignant biological behavior of glioma cells. Mol Ther. 2020;28:613\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2019.11.015.","journal-title":"Mol Ther"},{"key":"3909_CR27","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306\u201316. https:\/\/doi.org\/10.1001\/jama.2017.18718.","journal-title":"JAMA"},{"key":"3909_CR28","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192\u2013202. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.011.","journal-title":"Eur J Cancer"},{"key":"3909_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033830","volume":"102","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang Q, Ma C, Huang Y, Ding HX, Lu JW, Wang J, Li X, Zhong YH, Li ZQ. Characteristics and management of tumor treating fields-related dermatological complications in patients with glioblastoma. Medicine. 2023;102: e33830. https:\/\/doi.org\/10.1097\/MD.0000000000033830.","journal-title":"Medicine"},{"key":"3909_CR30","doi-asserted-by":"publisher","unstructured":"Ravin R, Cai TX, Li A, Briceno N, Pursley RH, Garmendia-Cedillos M, Pohida T, Wang H, Zhuang Z, Cui J, Morgan NY, Williamson NH, Gilbert MR, Basser PJ. \u201cTumor Treating Fields\u201d delivered via electromagnetic induction have varied effects across glioma cell lines and electric field amplitudes. bioRxiv 2023;14:562\u2013584. https:\/\/doi.org\/10.1101\/2023.01.18.524504","DOI":"10.1101\/2023.01.18.524504"},{"key":"3909_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","volume":"26","author":"ED Kirson","year":"2009","unstructured":"Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, Wasserman Y, Ryffel B, Goldsher D, Palti Y. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26:633\u201340. https:\/\/doi.org\/10.1007\/s10585-009-9262-y.","journal-title":"Clin Exp Metastasis"},{"key":"3909_CR32","doi-asserted-by":"publisher","unstructured":"Tatsui CE, Carlson KW, Patel CB. Tumor treating fields (TTFields) for spinal metastasis-The case for bone removal and spinal implants as waveguides to enhance field strength at the target. Neurooncol Adv 2024;6:vdad170 https:\/\/doi.org\/10.1093\/noajnl\/vdad170","DOI":"10.1093\/noajnl\/vdad170"},{"key":"3909_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","volume":"15","author":"S Lantuejoul","year":"2020","unstructured":"Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba II, Mino-Kenudson M. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol. 2020;15:499\u2013519. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.107.","journal-title":"J Thorac Oncol"},{"key":"3909_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13402-019-00470-y","volume":"43","author":"M Yousefi","year":"2020","unstructured":"Yousefi M, Ghaffari P, Nosrati R, Dehghani S, Salmaninejad A, Abarghan YJ, Ghaffari SH. Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. Cell Oncol. 2020;43:31\u201349. https:\/\/doi.org\/10.1007\/s13402-019-00470-y.","journal-title":"Cell Oncol"},{"key":"3909_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2217\/bmm-2020-0242","volume":"14","author":"S Fuschillo","year":"2020","unstructured":"Fuschillo S, Battiloro C, Rocco D, GravaraMottaManiscalco LDAM. Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer. Biomark Med. 2020;14:929\u201332. https:\/\/doi.org\/10.2217\/bmm-2020-0242.","journal-title":"Biomark Med"},{"key":"3909_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.lungcan.2013.06.025","volume":"81","author":"M Pless","year":"2013","unstructured":"Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I\/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81:445\u201350. https:\/\/doi.org\/10.1016\/j.lungcan.2013.06.025.","journal-title":"Lung Cancer"},{"key":"3909_CR37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","volume":"24","author":"T Leal","year":"2023","unstructured":"Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, Roubec J, Petruzelka L, Havel L, Kalmadi S, Ward J, Andric Z, Berghmans T, Gerber DE, Kloecker G, Panikkar R, Aerts J, Delmonte A, Pless M, Greil R, Rolfo C, Akerley W, Eaton M, Iqbal M, Langer C, Investigators LS. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet Oncol. 2023;24:1002\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(23)00344-3.","journal-title":"Lancet Oncol"},{"key":"3909_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.136","volume":"8","author":"NK Karanam","year":"2017","unstructured":"Karanam NK, Srinivasan K, Ding L, Sishc B, Saha D, Story MD. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. Cell Death Dis. 2017;8: e2711. https:\/\/doi.org\/10.1038\/cddis.2017.136.","journal-title":"Cell Death Dis"},{"issue":"Suppl 6","key":"3909_CR39","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","volume":"41","author":"M Giladi","year":"2014","unstructured":"Giladi M, Weinberg U, Schneiderman RS, Porat Y, Munster M, Voloshin T, Blatt R, Cahal S, Itzhaki A, Onn A, Kirson ED, Palti Y. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014;41(Suppl 6):S35-41. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.09.006.","journal-title":"Semin Oncol"},{"key":"3909_CR40","first-page":"2673","volume":"12","author":"WS Lee","year":"2022","unstructured":"Lee WS, Kim EH. Combination therapy of doxorubicin with TTFields and radiation: newer approaches to combat lung cancer. Am J Cancer Res. 2022;12:2673\u201385.","journal-title":"Am J Cancer Res"},{"key":"3909_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semcancer.2020.05.010","volume":"72","author":"KK Wong","year":"2021","unstructured":"Wong KK. DNMT1: A key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198\u2013213. https:\/\/doi.org\/10.1016\/j.semcancer.2020.05.010.","journal-title":"Semin Cancer Biol"},{"key":"3909_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84: 106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535.","journal-title":"Int Immunopharmacol"},{"key":"3909_CR43","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.2147\/OTT.S247776","volume":"13","author":"C Zhang","year":"2020","unstructured":"Zhang C, Wang J, Zhang J, Qu H, Tang X. LINC00461 overexpression can induce docetaxel resistance in breast cancer by interacting with miR-411-5p. Onco Targets Ther. 2020;13:5551\u201362. https:\/\/doi.org\/10.2147\/OTT.S247776.","journal-title":"Onco Targets Ther"},{"key":"3909_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12672-023-00647-w","volume":"14","author":"AR Smothers","year":"2023","unstructured":"Smothers AR, Henderson JR, O\u2019Connell JJ, Stenbeck JM, Dean D, Harvey TG, Booth BW. Efficacy and selectivity of tumor-treating field therapy for triple-negative breast cancer cells via in-house delivery device. Discov Oncol. 2023;14:34. https:\/\/doi.org\/10.1007\/s12672-023-00647-w.","journal-title":"Discov Oncol"},{"key":"3909_CR45","first-page":"3935","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS, Cho JM, Kim H, Jeong YK, Kim JK, Kim EH. Tumor treating fields can effectively overcome trastuzumab resistant breast cancer multiplication. Am J Cancer Res. 2021;11:3935\u201345.","journal-title":"Am J Cancer Res"},{"key":"3909_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/1471-2407-10-229","volume":"10","author":"RS Schneiderman","year":"2010","unstructured":"Schneiderman RS, Shmueli E, Kirson ED, Palti Y. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer. 2010;10:229. https:\/\/doi.org\/10.1186\/1471-2407-10-229.","journal-title":"BMC Cancer"},{"key":"3909_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.hoc.2020.08.010","volume":"35","author":"SM Ostrowski","year":"2021","unstructured":"Ostrowski SM, Fisher DE. Biology of Melanoma. Hematol Oncol Clin North Am. 2021;35:29\u201356. https:\/\/doi.org\/10.1016\/j.hoc.2020.08.010.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3909_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40169-016-0102-9","volume":"5","author":"J Li","year":"2016","unstructured":"Li J, Guo C, Wang Z, Gao K, Shi X, Liu J. Electrical stimulation towards melanoma therapy via liquid metal printed electronics on skin. Clin Transl Med. 2016;5:21. https:\/\/doi.org\/10.1186\/s40169-016-0102-9.","journal-title":"Clin Transl Med"},{"key":"3909_CR49","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1136\/gutjnl-2014-309086","volume":"64","author":"EH Schreuders","year":"2015","unstructured":"Schreuders EH, Ruco A, Rabeneck L, Schoen RE, Sung JJ, Young GP, Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637\u201349. https:\/\/doi.org\/10.1136\/gutjnl-2014-309086.","journal-title":"Gut"},{"key":"3909_CR50","doi-asserted-by":"crossref","unstructured":"Duan B, Zhao Y, Bai J, Wang J, Duan X, Luo X, Zhang R, Pu Y, Kou M, Lei J, Yang S. Colorectal Cancer: An Overview. In: Morgado-Diaz JA (editor) Gastrointestinal Cancers. Brisbane (AU); 2022.","DOI":"10.36255\/exon-publications-gastrointestinal-cancers-colorectal-cancer"},{"key":"3909_CR51","doi-asserted-by":"publisher","unstructured":"Lee YJ, Cho JM, Sai S, Oh JY, Park JA, Oh SJ, Park M, Kwon J, Shin US, Beak JH, Lim SH, Song JY, Hwang SG, Kim EH. 5-Fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy. Cancers 2019;11:1999 https:\/\/doi.org\/10.3390\/cancers11121999","DOI":"10.3390\/cancers11121999"},{"key":"3909_CR52","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/0008-5472.can-04-0083","volume":"64","author":"ED Kirson","year":"2004","unstructured":"Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64:3288\u201395. https:\/\/doi.org\/10.1158\/0008-5472.can-04-0083.","journal-title":"Cancer Res"},{"key":"3909_CR53","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2011.197","volume":"19","author":"E Manchado","year":"2012","unstructured":"Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ. 2012;19:369\u201377. https:\/\/doi.org\/10.1038\/cdd.2011.197.","journal-title":"Cell Death Differ"},{"key":"3909_CR54","doi-asserted-by":"publisher","DOI":"10.3791\/58937","author":"MM Riley","year":"2019","unstructured":"Riley MM, San P, Lok E, Swanson KD, Wong ET. The clinical application of tumor treating fields therapy in glioblastoma. J Vis Exp. 2019. https:\/\/doi.org\/10.3791\/58937.","journal-title":"J Vis Exp"},{"key":"3909_CR55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","volume":"14","author":"M Giladi","year":"2014","unstructured":"Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, Cahal S, Kirson ED, Weinberg U, Palti Y. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology. 2014;14:54\u201363. https:\/\/doi.org\/10.1016\/j.pan.2013.11.009.","journal-title":"Pancreatology"},{"key":"3909_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125269","volume":"10","author":"N Gera","year":"2015","unstructured":"Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS ONE. 2015;10: e0125269. https:\/\/doi.org\/10.1371\/journal.pone.0125269.","journal-title":"PLoS ONE"},{"key":"3909_CR57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000469690","volume":"32","author":"ET Wong","year":"2018","unstructured":"Wong ET, Lok E, Swanson KD. Alternating electric fields therapy for malignant gliomas: from bench observation to clinical reality. Prog Neurol Surg. 2018;32:180\u201395. https:\/\/doi.org\/10.1159\/000469690.","journal-title":"Prog Neurol Surg"},{"key":"3909_CR58","doi-asserted-by":"publisher","unstructured":"Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schuler U, Zips D, Eckert F, Huber SM. Alternating Electric Fields (TTFields) Activate Ca(v)1.2 Channels in Human Glioblastoma Cells. Cancers 2019;11:110 https:\/\/doi.org\/10.3390\/cancers11010110","DOI":"10.3390\/cancers11010110"},{"key":"3909_CR59","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.cmet.2021.04.002","volume":"33","author":"MR Zanotelli","year":"2021","unstructured":"Zanotelli MR, Zhang J, Reinhart-King CA. Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. 2021;33:1307\u201321. https:\/\/doi.org\/10.1016\/j.cmet.2021.04.002.","journal-title":"Cell Metab"},{"key":"3909_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.171","volume":"8","author":"M Silginer","year":"2017","unstructured":"Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis. 2017;8: e2753. https:\/\/doi.org\/10.1038\/cddis.2017.171.","journal-title":"Cell Death Dis"},{"key":"3909_CR61","doi-asserted-by":"publisher","first-page":"153303382094748","DOI":"10.1177\/1533033820947481","volume":"19","author":"JY Oh","year":"2020","unstructured":"Oh JY, Lee YJ, Kim EH. Tumor-treating fields inhibit the metastatic potential of osteosarcoma cells. Technol Cancer Res Treat. 2020;19:1533033820947481. https:\/\/doi.org\/10.1177\/1533033820947481.","journal-title":"Technol Cancer Res Treat"},{"key":"3909_CR62","doi-asserted-by":"publisher","unstructured":"Pittayapruek P, Meephansan J, Prapapan O, Komine M, Ohtsuki M. Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis. Int J Mol Sci 2016;17:868 https:\/\/doi.org\/10.3390\/ijms17060868","DOI":"10.3390\/ijms17060868"},{"key":"3909_CR63","doi-asserted-by":"publisher","first-page":"65125","DOI":"10.18632\/oncotarget.11372","volume":"7","author":"EH Kim","year":"2016","unstructured":"Kim EH, Song HS, Yoo SH, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. Oncotarget. 2016;7:65125\u201336. https:\/\/doi.org\/10.18632\/oncotarget.11372.","journal-title":"Oncotarget"},{"key":"3909_CR64","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495\u2013516. https:\/\/doi.org\/10.1080\/01926230701320337.","journal-title":"Toxicol Pathol"},{"key":"3909_CR65","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, Schneiderman RS, Voloshin T, Porat Y, Munster M, Blat R, Sherbo S, Bomzon Z, Urman N, Itzhaki A, Cahal S, Shteingauz A, Chaudhry A, Kirson ED, Weinberg U, Palti Y. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:18046. https:\/\/doi.org\/10.1038\/srep18046.","journal-title":"Sci Rep"},{"key":"3909_CR66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41420-018-0079-9","volume":"4","author":"AF Kessler","year":"2018","unstructured":"Kessler AF, Frombling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, Lohr M, Hagemann C. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov. 2018;4:12. https:\/\/doi.org\/10.1038\/s41420-018-0079-9.","journal-title":"Cell Death Discov"},{"key":"3909_CR67","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/cns.13441","volume":"26","author":"H Wu","year":"2020","unstructured":"Wu H, Wang C, Liu J, Zhou D, Chen D, Liu Z, Wu A, Yang L, Chang J, Luo C, Cheng W, Shen S, Bai Y, Mu X, Li C, Wang Z, Chen L. Evaluation of a tumor electric field treatment system in a rat model of glioma. CNS Neurosci Ther. 2020;26:1168\u201377. https:\/\/doi.org\/10.1111\/cns.13441.","journal-title":"CNS Neurosci Ther"},{"key":"3909_CR68","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10495-023-01811-x","volume":"28","author":"H Xu","year":"2023","unstructured":"Xu H, Shen X, Li X, Yang X, Chen C, Luo D. The natural product dehydrocurvularin induces apoptosis of gastric cancer cells by activating PARP-1 and caspase-3. Apoptosis. 2023;28:525\u201338. https:\/\/doi.org\/10.1007\/s10495-023-01811-x.","journal-title":"Apoptosis"},{"key":"3909_CR69","doi-asserted-by":"publisher","first-page":"153303381984500","DOI":"10.1177\/1533033819845008","volume":"18","author":"Y Jo","year":"2019","unstructured":"Jo Y, Sung J, Jeong H, Hong S, Jeong YK, Kim EH, Yoon M. Effectiveness of a fractionated therapy scheme in tumor treating fields therapy. Technol Cancer Res Treat. 2019;18:1533033819845008. https:\/\/doi.org\/10.1177\/1533033819845008.","journal-title":"Technol Cancer Res Treat"},{"key":"3909_CR70","doi-asserted-by":"publisher","first-page":"6630","DOI":"10.1038\/s41388-019-0882-7","volume":"38","author":"EH Kim","year":"2019","unstructured":"Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, Lee YJ, Cho JM, Kwak SY, Baek JH, Jeong YK, Song JY, Yoon M, Hwang SG. Tumor-treating fields induce autophagy by blocking the Akt2\/miR29b axis in glioblastoma cells. Oncogene. 2019;38:6630\u201346. https:\/\/doi.org\/10.1038\/s41388-019-0882-7.","journal-title":"Oncogene"},{"key":"3909_CR71","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","volume":"24","author":"J Debnath","year":"2023","unstructured":"Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24:560\u201375. https:\/\/doi.org\/10.1038\/s41580-023-00585-z.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3909_CR72","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/s41419-018-1085-9","volume":"9","author":"A Shteingauz","year":"2018","unstructured":"Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, Kaynan N, Gotlib K, Giladi M, Kirson ED, Weinberg U, Kinzel A, Palti Y. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death Dis. 2018;9:1074. https:\/\/doi.org\/10.1038\/s41419-018-1085-9.","journal-title":"Cell Death Dis"},{"key":"3909_CR73","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860\u201375. https:\/\/doi.org\/10.1038\/nrc3380.","journal-title":"Nat Rev Cancer"},{"key":"3909_CR74","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","volume":"69","author":"T Voloshin","year":"2020","unstructured":"Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RS, Zeevi E, Munster M, Blat R, Tempel Brami C, Cahal S, Itzhaki A, Giladi M, Kirson ED, Weinberg U, Kinzel A, Palti Y. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69:1191\u2013204. https:\/\/doi.org\/10.1007\/s00262-020-02534-7.","journal-title":"Cancer Immunol Immunother"},{"key":"3909_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372. https:\/\/doi.org\/10.1146\/annurev-immunol-032712-100008.","journal-title":"Annu Rev Immunol"},{"key":"3909_CR76","doi-asserted-by":"publisher","unstructured":"Park JI, Song KH, Jung SY, Ahn J, Hwang SG, Kim J, Kim EH, Song JY. Tumor-treating fields induce RAW264.7 macrophage activation via NK-kappaB\/MAPK signaling pathways. Technol Cancer Res Treat 2019;18:1533033819868225 https:\/\/doi.org\/10.1177\/1533033819868225","DOI":"10.1177\/1533033819868225"},{"key":"3909_CR77","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","volume":"124","author":"O Rominiyi","year":"2021","unstructured":"Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y, Collis SJ. Tumour treating fields therapy for glioblastoma: current advances and future directions. Br J Cancer. 2021;124:697\u2013709. https:\/\/doi.org\/10.1038\/s41416-020-01136-5.","journal-title":"Br J Cancer"},{"key":"3909_CR78","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1038\/s41598-020-59445-x","volume":"10","author":"YN Yoon","year":"2020","unstructured":"Yoon YN, Lee DS, Park HJ, Kim JS. Barium titanate nanoparticles sensitise treatment-resistant breast cancer cells to the antitumor action of tumour-treating fields. Sci Rep. 2020;10:2560. https:\/\/doi.org\/10.1038\/s41598-020-59445-x.","journal-title":"Sci Rep"},{"key":"3909_CR79","doi-asserted-by":"publisher","unstructured":"Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, Bomzon Z, Patel CB. Permeabilizing cell membranes with electric fields. Cancers 2021;13:2283 https:\/\/doi.org\/10.3390\/cancers13092283","DOI":"10.3390\/cancers13092283"},{"key":"3909_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119491","volume":"224","author":"J Xie","year":"2019","unstructured":"Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224: 119491. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119491.","journal-title":"Biomaterials"},{"key":"3909_CR81","doi-asserted-by":"publisher","unstructured":"Salvador E, Kessler AF, Domrose D, Hormann J, Schaeffer C, Giniunaite A, Burek M, Tempel-Brami C, Voloshin T, Volodin A, Zeidan A, Giladi M, Ernestus RI, Lohr M, Forster CY, Hagemann C. Tumor treating fields (TTFields) reversibly permeabilize the blood-brain barrier in vitro and in vivo. Biomolecules 2022;12:1348 https:\/\/doi.org\/10.3390\/biom12101348","DOI":"10.3390\/biom12101348"},{"key":"3909_CR82","doi-asserted-by":"publisher","unstructured":"Lin Y, Chen B. Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma. Ann Transl Med 2021;9:1804. https:\/\/doi.org\/10.21037\/atm-21-4760","DOI":"10.21037\/atm-21-4760"},{"key":"3909_CR83","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.6004\/jnccn.2016.0145","volume":"14","author":"SK Meletath","year":"2016","unstructured":"Meletath SK, Pavlick D, Brennan T, Hamilton R, Chmielecki J, Elvin JA, Palma N, Ross JS, Miller VA, Stephens PJ, Snipes G, Rajaram V, Ali SM, Melguizo-Gavilanes I. Personalized treatment for a patient With a BRAF V600E mutation using dabrafenib and a tumor treatment fields device in a high-grade glioma arising from ganglioglioma. J Natl Compr Canc Netw. 2016;14:1345\u201350. https:\/\/doi.org\/10.6004\/jnccn.2016.0145.","journal-title":"J Natl Compr Canc Netw"},{"key":"3909_CR84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","volume":"29","author":"G Ozcan","year":"2023","unstructured":"Ozcan G, Singh M, Vredenburgh JJ. Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments. Clin Cancer Res. 2023;29:11\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1585.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03909-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03909-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03909-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:02:41Z","timestamp":1756893761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03909-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":84,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["3909"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03909-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}